酒皶アトラス

出版社： 中外医学社
著者：
発行日： 2022-08-05
分野： 臨床医学：内科  >  皮膚科
ISBN： 9784498063822
電子書籍版： 2022-08-05 （1版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

5,280 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

5,280 円(税込)

購入する

商品紹介

ありふれた疾患で悩んでいる人が多いにも関わらず，今に至っても正しい診療が行われているとは言い難い「酒皶」．時には間違った診断による不要な治療で症状が増悪するケースも生じている．本書は，そんな皮膚科学の進歩から取り残された酒皶をメインテーマとした，初めてのスタンダードテキストだ．豊富な診療実績を誇る著者が100を超える症例写真を元に，酒皶とその近縁疾患の診かたを解説した．赤ら顔診療の新バイブルと言える．

目次

  • 第1章　総論

    1．酒皶の概念・診断
    2．酒皶様皮膚炎の概念・診断
    3．毛包虫症の概念・診断
    4．毛包虫増加に寄与する因子
    5．毛包虫の病態への関与
    6．鑑別診断
    7．酒皶の治療
    8．酒皶様皮膚炎の治療
    9．毛包虫症の治療
    10．酒皶やその類症の治療の実際

    第2章　症例提示（治療前後）

    1．酒皶・酒皶様皮膚炎
    　　　症例　1　67歳　女性

    2．酒皶・毛包虫症
    　　　症例　1　49歳　女性
    　　　症例　2　53歳　女性
    　　　症例　3　43歳　女性
    　　　症例　4　37歳　女性
    　　　症例　5　23歳　女性
    　　　症例　6　58歳　女性
    　　　症例　7　30歳　女性
    　　　症例　8　66歳　女性
    　　　症例　9　35歳　女性
    　　　症例　10　30歳　男性
    　　　症例　11　23歳　女性
    　　　症例　12　74歳　女性
    　　　症例　13　45歳　女性
    　　　症例　14　33歳　男性
    　　　症例　15　24歳　女性
    　　　症例　16　54歳　女性

    3．酒皶・酒皶様皮膚炎・毛包虫症
    　　　症例　1　50歳　女性
    　　　症例　2　45歳　女性
    　　　症例　3　49歳　女性
    　　　症例　4　73歳　女性
    　　　症例　5　48歳　男性
    　　　症例　6　74歳　女性
    　　　症例　7　48歳　女性
    　　　症例　8　48歳　女性
    　　　症例　9　53歳　女性
    　　　症例　10　25歳　女性
    　　　症例　11　69歳　女性
    　　　症例　12　47歳　女性
    　　　症例　13　81歳　女性
    　　　症例　14　49歳　女性
    　　　症例　15　29歳　女性
    　　　症例　16　35歳　女性
    　　　症例　17　46歳　女性
    　　　症例　18　61歳　女性
    　　　症例　19　61歳　男性
    　　　症例　20　42歳　女性
    　　　症例　21　40歳　女性

    4．酒皶やその類症＋尋常性痤瘡
    　　　症例　1　65歳　女性
    　　　症例　2　17歳　女性
    　　　症例　3　26歳　女性
    　　　症例　4　14歳　女性
    　　　症例　5　25歳　女性
    　　　症例　6　25歳　男性
    　　　症例　7　43歳　女性
    　　　症例　8　34歳　女性
    　　　症例　9　57歳　女性
    　　　症例　10　23歳　男性
    　　　症例　11　34歳　女性
    　　　症例　12　31歳　女性
    　　　症例　13　40歳　女性
    　　　症例　14　58歳　女性

    5．酒皶やその類症＋アトピー性皮膚炎
    　　　症例　1　53歳　女性
    　　　症例　2　22歳　女性
    　　　症例　3　39歳　女性
    　　　症例　4　32歳　女性
    　　　症例　5　46歳　女性
    　　　症例　6　51歳　女性
    　　　症例　7　41歳　男性
    　　　症例　8　47歳　女性
    　　　症例　9　44歳　女性
    　　　症例　10　28歳　女性
    　　　症例　11　7歳　女児
    　　　症例　12　33歳　女性
    　　　症例　13　32歳　女性
    　　　症例　14　40歳　女性
    　　　症例　15　27歳　女性
    　　　症例　16　43歳　女性
    　　　症例　17　35歳　女性
    　　　症例　18　8歳　男児
    　　　症例　19　41歳　女性

    6．酒皶やその類症＋花粉皮膚炎
    　　　症例　1　50歳　女性
    　　　症例　2　51歳　女性
    　　　症例　3　45歳　女性
    　　　症例　4　43歳　女性
    　　　症例　5　43歳　女性
    　　　症例　6　56歳　女性
    　　　症例　7　51歳　女性
    　　　症例　8　28歳　女性
    　　　症例　9　26歳　女性

    7．酒皶やその類症＋脂漏性皮膚炎
    　　　症例　1　52歳　男性
    　　　症例　2　33歳　女性
    　　　症例　3　77歳　女性

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 総論

P.5 掲載の参考文献
1) van Zuuren EJ. Rosacea. N Engl J Med. 2017 ; 377 : 1754-64.
PubMed
2) Gether L, Overgaard LK, Egeberg A, et al. Incidence and prevalence of rosacea : a systematic review and meta-analysis. Br J Dermatol. 2018 ; 179 : 282-9.
PubMed
3) Rueda LJ, Motta A, Pabon JG, et al. Epidemiology of rosacea in Colombia. Int J Dermatol. 2017 ; 56 : 510-3.
PubMed
4) Tan J, Schofer H, Araviiskaia E, et al. Prevalence of rosacea in the general population of Germany and Russia-The RISE study. J Eur Acad Dermatol Venereol. 2016 ; 30 : 428-34.
PubMed
5) Spoendlin J, Voegel JJ, Jick SS, et al. A study on the epidemiology of rosacea in the U. K. Br J Dermatol. 2012 ; 167 : 598-605.
 
6) Gupta N, Dhawan A, Beri S, et al. Clinical spectrum of pediatric blepharokeratoconjunctivitis. J AAPOS. 2010 ; 14 : 527-9.
PubMed
7) Ghanem VC, Mehra N, Wong S, et al. The prevalence of ocular signs in acne rosacea : comparing patients from ophthalmology and dermatology clinics. Cornea. 2003 ; 22 : 230-3.
PubMed
8) Wollina U. Rosacea and rhinophyma in the elderly. Clin Dermatol. 2011 ; 29 : 61-8.
PubMed
9) Alexis AF, Callender VD, Baldwin HE, et al. Global epidemiology and clinical spectrum of rosacea, highlighting skin of color : review and clinical practice experience. J Am Acad Dermatol. 2019 ; 80 : 1722-9 e1727.
 
10) Tavassoli S, Wong N, Chan E. Ocular manifestations of rosacea : a clinical review. Clin Exp Ophthalmol. 2021 ; 49 : 104-17.
PubMed
11) Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea : report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002 ; 46 : 584-7.
PubMed
12) Tan J, Almeida LM, Bewley A, et al. Updating the diagnosis, classification and assessment of rosacea : recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017 ; 176 : 431-8.
PubMed
13) Schaller M, Almeida LMC, Bewley A, et al. Recommendations for rosacea diagnosis, classification and management : update from the global ROSacea COnsensus 2019 panel. Br J Dermatol. 2020 ; 182 : 1269-76.
PubMed
P.7 掲載の参考文献
1) Tempark T, Shwayder TA. Perioral dermatitis : a review of the condition with special attention to treatment options. Am J Clin Dermatol. 2014 ; 15 : 101-13.
PubMed
2) Tolaymat L, Hall MR. Perioral Dermatitis. In : Stat-Pearls [Internet]. Treasure Island (FL) : StatPearls Publishing ; 2020.
 
3) Hogan DJ, Epstein JD, Lane PR. Perioral dermatitis : an uncommon condition? CMAJ. 1986 ; 134 : 1025-8.
PubMed
4) Lipozencic J, Hadzavdic SL. Perioral dermatitis. Clin Dermatol. 2014 ; 32 : 125-30.
PubMed
5) Teraki Y, Hitomi K, Sato Y, et al. Tacrolimus-induced rosacea-like dermatitis : a clinical analysis of 16 cases associated with tacrolimus ointment application. Dermatology. 2012 ; 224 : 309-14.
PubMed
6) Urbatsch AJ, Frieden I, Williams ML, et al. Extrafacial and generalized granulomatous periorificial dermatitis. Arch Dermatol. 2002 ; 138 : 1354-8.
PubMed
7) Peralta L, Morais P. Perioral dermatitis-- the role of nasal steroids. Cutan Ocul Toxicol. 2012 ; 31 : 160-3.
PubMed
8) Poulos GA, Brodell RT. Perioral dermatitis associated with an inhaled corticosteroid. Arch Dermatol. 2007 ; 143 : 1460.
PubMed
9) Bradford LG, Montes LF. Perioral dermatitis and Candida albicans. Arch Dermatol. 1972 ; 105 : 892-5.
PubMed
10) Takiwaki H, Tsuda H, Arase S, et al. Differences between intrafollicular microorganism profiles in perioral and seborrhoeic dermatitis. Clin Exp Dermatol. 2003 ; 28 : 531-4.
PubMed
11) Dolenc-Voljc M, Pohar M, Lunder T. Density of Demodex folliculorum in perioral dermatitis. Acta Derm Venereol. 2005 ; 85 : 211-5.
PubMed
12) Peters P, Drummond C. Perioral dermatitis from high fluoride dentifrice : a case report and review of literature. Aust Dent J. 2013 ; 58 : 371-2.
PubMed
13) Satyawan I, Oranje AP, van Joost T. Perioral dermatitis in a child due to rosin in chewing gum. Contact Dermatitis. 1990 ; 22 : 182-3.
 
14) Guarneri F, Marini H. Perioral dermatitis after dental filling in a 12-year-old girl : involvement of cholinergic system in skin neuroinflammation? ScientificWorldJournal. 2008 ; 8 : 157-63.
 
15) Malik R, Quirk CJ. Topical applications and perioral dermatitis. Australas J Dermatol. 2000 ; 41 : 34-8.
PubMed
16) Abeck D, Geisenfelder B, Brandt O. Physical sunscreens with high sun protection factor may cause perioral dermatitis in children. J Dtsch Dermatol Ges. 2009 ; 7 : 701-3.
 
17) Spirov G, Berova N, Vassilev D. Effect of oral inhibitors of ovulation in treatment of rosacea and dermatitis perioralis in women. Australas J Dermatol. 1971 ; 12 : 145-54.
PubMed
18) Marks R, Black MM. Perioral dermatitis. A histopathologic study of 26 cases. Br J Dermatol. 1971 ; 84 : 242-7.
PubMed
19) Frieden IJ, Prose NS, Fletcher V, et al. Granulomatous perioral dermatitis in children. Arch Dermatol. 1989 ; 125 : 369-73.
PubMed
P.11 掲載の参考文献
1) Forton FMN. The pathogenic role of demodex mites in rosacea : a potential therapeutic target already in erythematotelangiectatic rosacea? Dermatol Ther (Heidelb). 2020 ; 10 : 1229-53.
PubMed
2) Rufli T, Mumcuoglu Y. The hair follicle mites Demodex folliculorum and Demodex brevis : biology and medical importance. A review. Dermatologica. 1981 ; 162 : 1-11.
PubMed
3) Nutting WB. Hair follicle mites (Acari : Demodicidae) of man. Int J Dermatol. 1976 ; 15 : 79-98.
PubMed
4) Thoemmes MS, Fergus DJ, Urban J, et al. Ubiquity and diversity of human-associated Demodex mites. PLoS One. 2014 ; 9 : e106265.
PubMed
5) Forton F, Germaux MA, Brasseur T, et al. Demodicosis and rosacea : epidemiology and significance in daily dermatologic practice. J Am Acad Dermatol. 2005 ; 52 : 74-87.
PubMed
6) Forton FMN. Papulopustular rosacea, skin immunity and Demodex : pityriasis folliculorum as a missing link. J Eur Acad Dermatol Venereol. 2012 ; 26 : 19-28.
 
7) Lacey N, Russell-Hallinan A, Zouboulis CC, et al. Demodex mites modulate sebocyte immune reaction : possible role in the pathogenesis of rosacea. Br J Dermatol. 2018 ; 179 : 420-30.
PubMed
8) Hsu HC. Physical function trajectories, depressive symptoms, and life satisfaction among the elderly in Taiwan. Aging Ment Health. 2009 ; 13 : 202-12.
PubMed
9) Chen W, Plewig G. Human demodicosis : revisit and a proposed classification. Br J Dermatol. 2014 ; 170 : 1219-25.
 
10) Shelley WB, Shelley ED, Burmeister V. Unilateral demodectic rosacea. J Am Acad Dermatol. 1989 ; 20 : 915-7.
PubMed
11) Zomorodian K, Geramishoar M, Saadat F, et al. Facial demodicosis. Eur J Dermatol. 2004 ; 14 : 121-2.
PubMed
12) Garcia-Vargas A, Mayorga-Rodriguez JA, Sandoval-Tress C. Scalp demodicidosis mimicking favus in a 6-year-old boy. J Am Acad Dermatol. 2007 ; 57 : S19-21.
 
13) Aydogan K, Alver O, Tore O, et al. Facial abscess-like conglomerates associated with Demodex mites. J Eur Acad Dermatol Venereol. 2006 ; 20 : 1002-4.
PubMed
14) Gilaberte Y, Frias MP, Rezusta A, et al. Photodynamic therapy with methyl aminolevulinate for resistant scalp folliculitis secondary to Demodex infestation. J Eur Acad Dermatol Venereol. 2009 ; 23 : 718-9.
PubMed
15) Ayres S, Jr., Ayres S, 3rd. Demodectic eruptions (demodicidosis) in the human. 30 years' experience with 2 commonly unrecognized entities : pityriasis folliculorum (Demodex) and acne rosacea (Demodex type). Arch Dermatol. 1961 ; 83 : 816-27.
PubMed
16) Schaller M, Sander CA, Plewig G. Demodex abscesses : clinical and therapeutic challenges. J Am Acad Dermatol. 2003 ; 49 : S272-4.
PubMed
17) Liu J, Sheha H, Tseng SC. Pathogenic role of Demodex mites in blepharitis. Curr Opin Allergy Clin Immunol. 2010 ; 10 : 505-10.
PubMed
18) Liang L, Ding X, Tseng SC. High prevalence of demodex brevis infestation in chalazia. Am J Ophthalmol. 2014 ; 157 : 342-8 e341.
 
19) Klemm E, Haroske G, Wollina U. Otitis externa and myringitis due to demodicidosis. Acta Dermatovenerol Alp Pannonica Adriat. 2009 ; 18 : 73-6.
PubMed
20) Forton F, Seys B. Density of Demodex folliculorum in rosacea : a case-control study using standardized skin-surface biopsy. Br J Dermatol. 1993 ; 128 : 650-9.
PubMed
21) Segal R, Mimouni D, Feuerman H, et al. Dermoscopy as a diagnostic tool in demodicidosis. Int J Dermatol. 2010 ; 49 : 1018-23.
PubMed
22) Longo C, Pellacani G, Ricci C, et al. In vivo detection of Demodex folliculorum by means of confocal microscopy. Br J Dermatol. 2012 ; 166 : 690-2.
PubMed
23) Maier T, Sattler E, Braun-Falco M, et al. High-definition optical coherence tomography for the in vivo detection of demodex mites. Dermatology. 2012 ; 225 : 271-6.
PubMed
24) Kheirkhah A, Blanco G, Casas V, et al. Fluorescein dye improves microscopic evaluation and counting of demodex in blepharitis with cylindrical dandruff. Cornea. 2007 ; 26 : 697-700.
PubMed
P.14 掲載の参考文献
1) Forton FMN. The pathogenic role of Demodex mites in rosacea : a potential therapeutic target already in erythematotelangiectatic rosacea? Dermatol Ther (Heidelb). 2020 ; 10 : 1229-53.
PubMed
2) Smith JR, Lanier VB, Braziel RM, et al. Expression of vascular endothelial growth factor and its receptors in rosacea. Br J Ophthalmol. 2007 ; 91 : 226-9.
PubMed
3) Gazi U, Gureser AS, Oztekin A, et al. Skin-homing T-cell responses associated with Demodex infestation and rosacea. Parasite Immunol. 2019 ; 41 : e12658.
PubMed
4) Voron T, Marcheteau E, Pernot S, et al. Control of the immune response by pro-angiogenic factors. Front Oncol. 2014 ; 4 : 70.
PubMed
5) Forton F, De Maertelaer V. Erythematotelangiectatic rosacea may be associated with a subclinical stage of demodicosis : a case-control study. Br J Dermatol. 2019 ; 181 : 818-25.
PubMed
6) Rahma OE, Hodi FS. The intersection between tumor angiogenesis and immune suppression. Clin Cancer Res. 2019 ; 25 : 5449-57.
PubMed
7) Kanitakis J, Al-Rifai I, Faure M, et al. Demodex mites of human skin express Tn but not T (Thomsen-Friedenreich) antigen immunoreactivity. J Cutan Pathol. 1997 ; 24 : 454-5.
 
8) Zaal A, Li RJE, Lubbers J, et al. Activation of the C-type lectin MGL by terminal GalNAc ligands reduces the glycolytic activity of human dendritic cells. Front Immunol. 2020 ; 11 : 305.
 
9) van Vliet SJ, van Liempt E, Geijtenbeek TB, et al. Differential regulation of C-type lectin expression on tolerogenic dendritic cell subsets. Immunobiology. 2006 ; 211 : 577-85.
PubMed
10) Stromberg BE, Nutting WB. Adaptive features of the exoskeleton and pigment deposits in Demodex spp. (Demodicidae). Acarologia. 1972 ; 14 : 605-11.
 
11) Tsutsumi Y. Deposition of IgD, alpha-1-antitrypsin and alpha-1-antichymotrypsin on Demodex folliculorum and D. brevis infesting the pilosebaceous unit. Pathol Int. 2004 ; 54 : 32-4.
 
12) Clanner-Engelshofen BM, French LE, Reinholz M. Corynebacterium kroppenstedtii subsp. demodicis is the endobacterium of Demodex folliculorum. J Eur Acad Dermatol Venereol. 2020 ; 34 : 1043-9.
PubMed
13) van Vliet SJ, Gringhuis SI, Geijtenbeek TB, et al. Regulation of effector T cells by antigen-presenting cells via interaction of the C-type lectin MGL with CD45. Nat Immunol. 2006 ; 7 : 1200-8.
 
14) van Vliet SJ, Bay S, Vuist IM, et al. MGL signaling augments TLR2-mediated responses for enhanced IL-10 and TNF-alpha secretion. J Leukoc Biol. 2013 ; 94 : 315-23.
PubMed
15) Brockmann L, Gagliani N, Steglich B, et al. IL-10 receptor signaling is essential for TR1 cell function in vivo. J Immunol. 2017 ; 198 : 1130-41.
PubMed
16) Sim WJ, Ahl PJ, Connolly JE. Metabolism is central to tolerogenic dendritic cell function. Mediators Inflamm. 2016 ; 2016 : 2636701.
PubMed
17) Kurtenkov O. Profiling of naturally occurring antibodies to the Thomsen-Friedenreich antigen in health and cancer : the diversity and clinical potential. Biomed Res Int. 2020 ; 2020 : 9747040.
 
18) Allakhverdi Z, Comeau MR, Jessup HK, et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med. 2007 ; 204 : 253-8.
PubMed
19) Dajnoki Z, Beke G, Kapitany A, et al. Sebaceous gland-rich skin is characterized by TSLP expression and distinct immune surveillance which is disturbed in rosacea. J Invest Dermatol. 2017 ; 137 : 1114-25.
PubMed
20) Ferreira GB, Vanherwegen AS, Eelen G, et al. Vitamin D3 induces tolerance in human dendritic cells by activation of intracellular metabolic pathways. Cell Rep. 2015 ; 10 : 711-25.
PubMed
21) Benessahraoui M, Paratte F, Plouvier E, et al. Demodicidosis in a child with xantholeukaemia associated with type 1 neurofibromatosis. Eur J Dermatol. 2003 ; 13 : 311-2.
 
22) Damian D, Rogers M. Demodex infestation in a child with leukaemia : treatment with ivermectin and permethrin. Int J Dermatol. 2003 ; 42 : 724-6.
 
23) Herron MD, O'Reilly MA, Vanderhooft SL. Refractory Demodex folliculitis in five children with acute lymphoblastic leukemia. Pediatr Dermatol. 2005 ; 22 : 407-11.
 
24) Jansen T, Kastner U, Kreuter A, et al. Rosacea-like demodicidosis associated with acquired immunodeficiency syndrome. Br J Dermatol. 2001 ; 144 : 139-42.
PubMed
25) Karincaoglu Y, Esrefoglu Seyhan M, Bayram N, et al. Incidence of Demodex folliculorum in patients with end stage chronic renal failure. Ren Fail. 2005 ; 27 : 495-9.
PubMed
26) Akdeniz S, Bahceci M, Tuzcu AK, et al. Is Demodex folliculorum larger in diabetic patients? J Eur Acad Dermatol Venereol. 2002 ; 16 : 539-41.
PubMed
27) Karincaoglu Y, Tepe B, Kalayci B, et al. Is Demodex folliculorum an aetiological factor in seborrhoeic dermatitis? Clin Exp Dermatol. 2009 ; 34 : e516-20.
PubMed
28) Serpil S, Ulku K, Cemil C, et al. Positivity of Demodex spp. in biopsy specimens of nevi. Trop Biomed. 2009 ; 26 : 51-6.
PubMed
29) Erbagci Z, Erbagci I, Erkilic S. High incidence of demodicidosis in eyelid basal cell carcinomas. Int J Dermatol. 2003 ; 42 : 567-71.
PubMed
30) Antille C, Saurat JH, Lubbe J. Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch Dermatol. 2004 ; 140 : 457-60.
PubMed
31) Lubbe J, Stucky L, Saurat JH. Rosaceiform dermatitis with follicular Demodex after treatment of facial atopic dermatitis with 1% pimecrolimus cream. Dermatology. 2003 ; 207 : 204-5.
PubMed
32) Gerber PA, Kukova G, Buhren BA, et al. Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors. Dermatology. 2011 ; 222 : 144-7.
PubMed
33) Nakagawa T, Sasaki M, Fujita K, et al. Demodex folliculitis on the trunk of a patient with mycosis fungoides. Clin Exp Dermatol. 1996 ; 21 : 148-50.
PubMed
34) Kulac M, Ciftci IH, Karaca S, et al. Clinical importance of Demodex folliculorum in patients receiving phototherapy. Int J Dermatol. 2008 ; 47 : 72-7.
PubMed
P.18 掲載の参考文献
1) Trompezinski S, Pernet I, Schmitt D, et al. UV radiation and prostaglandin E2 up-regulate vascular endothelial growth factor (VEGF) in cultured human fibroblasts. Inflamm Res. 2001 ; 50 : 422-7.
PubMed
2) Gomaa AH, Yaar M, Eyada MM, et al. Lymphangiogenesis and angiogenesis in non-phymatous rosacea. J Cutan Pathol. 2007 ; 34 : 748-53.
PubMed
3) Voron T, Marcheteau E, Pernot S, et al. Control of the immune response by pro-angiogenic factors. Front Oncol. 2014 ; 4 : 70.
PubMed
4) Sim WJ, Ahl PJ, Connolly JE. Metabolism is central to tolerogenic dendritic cell function. Mediators Inflamm. 2016 ; 2016 : 2636701.
PubMed
5) Dajnoki Z, Beke G, Kapitany A, et al. Sebaceous gland-rich skin is characterized by TSLP expression and distinct immune surveillance which is disturbed in rosacea. J Invest Dermatol. 2017 ; 137 : 1114-25.
PubMed
6) Yamasaki K, Kanada K, Macleod DT, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol. 2011 ; 131 : 688-97.
PubMed
7) Lacey N, Russell-Hallinan A, Zouboulis CC, et al. Demodex mites modulate sebocyte immune reaction : possible role in the pathogenesis of rosacea. Br J Dermatol. 2018 ; 179 : 420-30.
PubMed
8) Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007 ; 13 : 975-80.
PubMed
9) Yamasaki K, Gallo RL. The molecular pathology of rosacea. J Dermatol Sci. 2009 ; 55 : 77-81.
PubMed
10) Kulkarni NN, Takahashi T, Sanford JA, et al. Innate immune dysfunction in rosacea promotes photosensitivity and vascular adhesion molecule expression. J Invest Dermatol. 2020 ; 140 : 645-55 e646.
 
11) Tolaymat L, Hall MR. Perioral dermatitis. In : Stat-Pearls [Internet]. Treasure Island (FL) : StatPearls Publishing ; 2020.
 
12) Perrigouard C, Peltre B, Cribier B. A histological and immunohistological study of vascular and inflammatory changes in rosacea. Ann Dermatol Venereol. 2013 ; 140 : 21-9.
PubMed
13) Aroni K, Tsagroni E, Lazaris AC, et al. Rosacea : a clinicopathological approach. Dermatology. 2004 ; 209 : 177-82.
PubMed
14) Ecker RI, Winkelmann RK. Demodex granuloma. Arch Dermatol. 1979 ; 115 : 343-4.
PubMed
15) Forton FMN. The Pathogenic role of Demodex mites in rosacea : a potential therapeutic target already in erythematotelangiectatic Rosacea? Dermatol Ther (Heidelb). 2020 ; 10 : 1229-53.
PubMed
16) Forton F, Seys B. Density of Demodex folliculorum in rosacea : a case-control study using standardized skin-surface biopsy. Br J Dermatol. 1993 ; 128 : 650-9.
PubMed
17) Erbagci Z, Ozgoztasi O. The significance of Demodex folliculorum density in rosacea. Int J Dermatol. 1998 ; 37 : 421-5.
PubMed
18) Chang YS, Huang YC. Role of Demodex mite infestation in rosacea : a systematic review and meta-analysis. J Am Acad Dermatol. 2017 ; 77 : 441-7e446.
PubMed
19) Tan J, Blume-Peytavi U, Ortonne JP, et al. An observational cross-sectional survey of rosacea : clinical associations and progression between subtypes. Br J Dermatol. 2013 ; 169 : 555-62.
PubMed
20) Forton F, De Maertelaer V. Erythematotelangiectatic rosacea may be associated with a subclinical stage of demodicosis : a case-control study. Br J Dermatol. 2019 ; 181 : 818-25.
PubMed
21) Smith JR, Lanier VB, Braziel RM, et al. Expression of vascular endothelial growth factor and its receptors in rosacea. Br J Ophthalmol. 2007 ; 91 : 226-9.
PubMed
22) Thyssen JP. Are demodex mites the best target for rosacea treatments? Br J Dermatol. 2019 ; 181 : 652-3.
PubMed
23) Baima B, Sticherling M. Demodicidosis revisited. Acta Derm Venereol. 2002 ; 82 : 3-6.
PubMed
24) Teraki Y, Hitomi K, Sato Y, et al. Tacrolimus-induced rosacea-like dermatitis : a clinical analysis of 16 cases associated with tacrolimus ointment application. Dermatology. 2012 ; 224 : 309-14.
PubMed
25) Adams SJ, Davison AM, Cunliffe WJ, et al. Perioral dermatitis in renal transplant recipients maintained on corticosteroids and immunosuppressive therapy. Br J Dermatol. 1982 ; 106 : 589-92.
PubMed
26) Dominey A, Tschen J, Rosen T, et al. Pityriasis folliculorum revisited. J Am Acad Dermatol. 1989 ; 21 : 81-4.
PubMed
27) Ayres S, Jr., Ayres S, 3rd. Demodectic eruptions (demodicidosis) in the human. 30 years' experience with 2 commonly unrecognized entities : pityriasis folliculorum (Demodex) and acne rosacea (Demodex type). Arch Dermatol. 1961 ; 83 : 816-27.
PubMed
28) Forton F. Demodex and perifollicular inflammation in man : review and report of 69 biopsies. Ann Dermatol Venereol. 1986 ; 113 : 1047-58.
PubMed
29) Forton FM. Papulopustular rosacea, skin immunity and Demodex : pityriasis folliculorum as a missing link. J Eur Acad Dermatol Venereol. 2012 ; 26 : 19-28.
 
30) Schaller M, Sander CA, Plewig G. Demodex abscesses : clinical and therapeutic challenges. J Am Acad Dermatol. 2003 ; 49 : S272-4.
PubMed
31) Zhang LJ. Type 1 Interferons potential initiating factors linking skin wounds with psoriasis pathogenesis. Front Immunol. 2019 ; 10 : 1440.
PubMed
P.22 掲載の参考文献
1) Hayashi N, Akamatsu H, Iwatsuki K, et al. Japanese Dermatological Association Guidelines : Guidelines for the treatment of acne vulgaris 2017. J Dermatol. 2018 ; 45 : 898-935.
PubMed
2) Wienholtz NKF, Christensen CE, Coskun H, et al. Infusion of pituitary adenylate cyclase-activating polypeptide-38 in patients with rosacea induces flushing and facial edema that can be attenuated by sumatriptan. J Invest Dermatol. 2021 ; 141 : 1687-98.
PubMed
3) Salo OP. SLE-like deposition of immunoglobulins in the skin in rosacea. A clinical and immunofluorescent study. Ann Clin Res. 1970 ; 2 : 28-31.
PubMed
4) Seiji M, Otaki N. Haber's syndrome. Familial rosacea-like dermatosis with keratotic plaques and pitted scars. Arch Dermatol. 1971 ; 103 : 452-5.
 
P.26 掲載の参考文献
1) Thiboutot D, Anderson R, Cook-Bolden F, et al. Standard management options for rosacea : The 2019 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2020 ; 82 : 1501-10.
 
2) Diczig B, Nemeth I, Sardy M, et al. Contact hypersensitivity in rosacea-a report on 143 cases. J Eur Acad Dermatol Venereol. 2018 ; 32 : e347-9.
 
3) Draelos ZD, Gunt H, Levy SB. Natural skin care products as adjunctive to prescription therapy in moderate to severe rosacea. J Drugs Dermatol. 2019 ; 18 : 141-6.
PubMed
4) Li G, Wang B, Zhao Z, et al. Excessive cleansing : an underestimating risk factor of rosacea in Chinese population. Arch Dermatol Res. 2020 ; 313 : 225-34.
PubMed
5) Johnson SM, Berg A, Barr C. Managing rosacea in the clinic : from pathophysiology to treatment-a review of the literature. J Clin Aesthet Dermatol. 2020 ; 13 : S17-22.
PubMed
6) Kresken J, Kindl U, Wigger-Alberti W, et al. Dermocosmetics for use in rosacea : Guideline of the Society for Dermopharmacy. Skin Pharmacol Physiol. 2018 ; 31 : 147-54.
 
7) Guertler A, Jontvedt NM, Clanner-Engelshofen BM, et al. Efficacy and safety results of micellar water, cream and serum for rosacea in comparison to a control group. J Cosmet Dermatol. 2020 ; 19 : 2627-33.
 
8) Baldwin H, Santoro F, Lachmann N, et al. A novel moisturizer with high sun protection factor improves cutaneous barrier function and the visible appearance of rosacea-prone skin. J Cosmet Dermatol. 2019 ; 18 : 1686-92.
PubMed
9) Santoro F, Lachmann N. An open-label, intra-individual study to evaluate a regimen of three cosmetic products combined with medical treatment of rosacea : cutaneous tolerability and effect on hydration. Dermatol Ther (Heidelb). 2019 ; 9 : 775-84.
PubMed
10) Anzengruber F, Czernielewski J, Conrad C, et al. Swiss S1 guideline for the treatment of rosacea. J Eur Acad Dermatol Venereol. 2017 ; 31 : 1775-91.
PubMed
11) Draelos ZD, Gold MH, Weiss RA, et al. Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea : findings from the 52-week open label REVEAL trial. J Am Acad Dermatol. 2018 ; 78 : 1156-63.
 
12) Fowler J, Jr., Jackson M, Moore A, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea : results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol. 2013 ; 12 : 650-6.
 
13) Draelos ZD, Elewski BE, Harper JC, et al. A phase 3 randomized, double-blind, vehicle-controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea. Cutis. 2015 ; 96 : 54-61.
PubMed
14) McClellan KJ, Noble S. Topical metronidazole. A review of its use in rosacea. Am J Clin Dermatol. 2000 ; 1 : 191-9.
PubMed
15) Taieb A, Ortonne JP, Ruzicka T, et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea : a randomized, investigator-blinded trial. Br J Dermatol. 2015 ; 172 : 1103-10.
 
16) Husein-ElAhmed H, Steinhoff M. Efficacy of topical ivermectin and impact on quality of life in patients with papulopustular rosacea : a systematic review and meta-analysis. Dermatol Ther. 2020 ; 33 : e13203.
PubMed
17) Trave I, Merlo G, Cozzani E, et al. Real-life experience on effectiveness and tolerability of topical ivermectin in papulopustular rosacea and antiparasitic effect on Demodex mites. Dermatol Ther. 2019 ; 32 : e13093.
PubMed
18) Shemer A, Shiri J, Mashiah J, et al. Topical minocycline foam for moderate to severe acne vulgaris : Phase 2 randomized double-blind, vehicle-controlled study results. J Am Acad Dermatol. 2016 ; 74 : 1251-2.
PubMed
19) Gold LS, Del Rosso JQ, Kircik L, et al. Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea : results of 2 phase 3, randomized, clinical trials. J Am Acad Dermatol. 2020 ; 82 : 1166-73.
PubMed
20) Webster G, Draelos ZD, Graber E, et al. A multicentre, randomized, double-masked, parallel group, vehicle-controlled phase IIb study to evaluate the safety and efficacy of 1% and 3% topical minocycline gel in patients with papulopustular rosacea. Br J Dermatol. 2020 ; 183 : 471-9.
 
21) Forton FMN, De Maertelaer V. Treatment of rosacea and demodicosis with benzyl benzoate : effects of different doses on Demodex density and clinical symptoms. J Eur Acad Dermatol Venereol. 2020 ; 34 : 365-9.
PubMed
22) Forton FMN, De Maertelaer V. Effectiveness of benzyl benzoate treatment on clinical symptoms and Demodex density over time in patients with rosacea and demodicosis : a real life retrospective follow-up study comparing low- and high-dose regimens. J Dermatolog Treat. 2020 : 1-10.
PubMed
23) Sheu SL. Treatment of melasma using tranexamic acid : what's known and what's next. Cutis. 2018 ; 101 : E7-8.
 
24) Bala HR, Lee S, Wong C, et al. Oral tranexamic acid for the treatment of melasma : a review. Dermatol Surg. 2018 ; 44 : 814-25.
PubMed
25) Kim MS, Chang SE, Haw S, et al. Tranexamic acid solution soaking is an excellent approach for rosacea patients : a preliminary observation in six patients. J Dermatol. 2013 ; 40 : 70-1.
PubMed
26) Bageorgou F, Vasalou V, Tzanetakou V, et al. The new therapeutic choice of tranexamic acid solution in treatment of erythematotelangiectatic rosacea. J Cosmet Dermatol. 2019 ; 18 : 563-7.
PubMed
27) Jakhar D, Kaur I, Misri R. Topical 10% Tranexamic acid for erythematotelangiectatic steriod induced rosacea. J Am Acad Dermatol. 2020 ; 86 : e1-2.
 
28) Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007 ; 56 : 791-802.
PubMed
29) Valentin S, Morales A, Sanchez JL, et al. Safety and efficacy of doxycycline in the treatment of rosacea. Clin Cosmet Investig Dermatol. 2009 ; 2 : 129-40.
PubMed
30) Sbidian E, Vicaut E, Chidiack H, et al. A randomized-controlled trial of oral low-dose isotretinoin for difficult-to-treat papulopustular rosacea. J Invest Dermatol. 2016 ; 136 : 1124-9.
PubMed
31) van Zuuren EJ, Fedorowicz Z, Tan J, et al. Interventions for rosacea based on the phenotype approach : an updated systematic review including GRADE assessments. Br J Dermatol. 2019 ; 181 : 65-79.
PubMed
32) Chen L, Tsai TF. The role of beta-blockers in dermatological treatment : a review. J Eur Acad Dermatol Venereol. 2018 ; 32 : 363-71.
PubMed
33) Logger JGM, Olydam JI, Driessen RJB. Use of beta-blockers for rosacea-associated facial erythema and flushing : a systematic review and update on proposed mode of action. J Am Acad Dermatol. 2020 ; 83 : 1088-97.
PubMed
34) Prabha N, Chhabra N, Arora R. Beta-blockers in dermatology. Indian J Dermatol Venereol Leprol. 2017 ; 83 : 399-407.
PubMed
35) Pietschke K, Schaller M. Long-term management of distinct facial flushing and persistent erythema of rosacea by treatment with carvedilol. J Dermatolog Treat. 2018 ; 29 : 310-3.
PubMed
36) Li J, Yuan X, Tang Y, et al. Hydroxychloroquine is a novel therapeutic approach for rosacea. Int Immunopharmacol. 2020 ; 79 : 106178.
 
37) Wang B, Yuan X, Huang X, et al. Efficacy and safety of hydroxychloroquine for treatment of patients with rosacea : a multicenter, randomized, double-blind, double-dummy, pilot study. J Am Acad Dermatol. 2021 ; 84 : 543-5.
PubMed
38) Kim BY, Moon HR, Ryu HJ. Comparative efficacy of short-pulsed intense pulsed light and pulsed dye laser to treat rosacea. J Cosmet Laser Ther. 2019 ; 21 : 291-6.
PubMed
39) Zhang Y, Jiang S, Lu Y, et al. A decade retrospective study of light/laser devices in treating nasal rosacea. J Dermatolog Treat. 2020 ; 31 : 84-90.
 
40) Kapicioglu Y, Sarac G, Cenk H. Treatment of erythematotelangiectatic rosacea, facial erythema, and facial telangiectasia with a 577-nm pro-yellow laser : a case series. Lasers Med Sci. 2019 ; 34 : 93-8.
 
41) Sun Y, Chen L, Zhang Y, et al. Topical photodynamic therapy with 5-aminolevulinic acid in Chinese patients with Rosacea. J Cosmet Laser Ther. 2019 ; 21 : 196-200.
PubMed
42) Fan L, Yin R, Lan T, et al. Photodynamic therapy for rosacea in Chinese patients. Photodiagnosis Photodyn Ther. 2018 ; 24 : 82-7.
PubMed
43) Baglieri F, Scuderi G. Treatment of recalcitrant granulomatous rosacea with ALA-PDT : report of a case. Indian J Dermatol Venereol Leprol. 2011 ; 77 : 536.
PubMed
44) Tanghetti EA, Goldberg DJ, Dover JS, et al. Oxymetazoline and energy-based therapy in patients with rosacea : evaluation of the safety and tolerability in an open-label, interventional study. Lasers Surg Med. 2021 ; 53 : 55-65.
 
45) Suggs AK, Macri A, Richmond H, et al. Treatment of erythematotelangiectatic rosacea with pulsed-dye laser and oxymetazoline 1.0% cream : a retrospective study. Lasers Surg Med. 2020 ; 52 : 38-43.
 
46) Deaver Peterson J, Katz TM. Open-label study assessing the efficacy and tolerability of topical skin care and sun protection alone and in combination with intense pulsed light therapy. J Cosmet Dermatol. 2019 ; 18 : 1758-64.
 
47) Kim MJ, Kim JH, Cheon HI, et al. Assessment of skin physiology change and safety after intradermal injections with botulinum toxin : a randomized, double-blind, placebo-controlled, split-face pilot study in rosacea patients with facial erythema. Dermatol Surg. 2019 ; 45 : 1155-62.
PubMed
48) Bharti J, Sonthalia S, Jakhar D. Mesotherapy with Botulinum toxin for the treatment of refractory vascular and papulopustular rosacea. J Am Acad Dermatol. 2018 ; S0190-9622 (18) 30808-9.
 
49) Al-Niaimi F, Glagoleva E, Araviiskaia E. Pulsed dye laser followed by intradermal botulinum toxin type-A in the treatment of rosacea-associated erythema and flushing. Dermatol Ther. 2020 ; 33 : e13976.
PubMed
50) Amir Ali A, Vender R, Vender R. The role of IL-17 in papulopustular rosacea and future directions. J Cutan Med Surg. 2019 ; 23 : 635-41.
PubMed
51) Kumar AM, Chiou AS, Shih YH, et al. An exploratory, open-label, investigator-initiated study of interleukin-17 blockade in patients with moderate-to-severe papulopustular rosacea. Br J Dermatol. 2020 ; 183 : 942-3.
PubMed
52) Jabbehdari S, Memar OM, Caughlin B, et al. Update on the pathogenesis and management of ocular rosacea : an interdisciplinary review. Eur J Ophthalmol. 2021 ; 31 : 22-33.
PubMed
53) Vazirnia A, Wat H, Danesh MJ, et al. Intense pulsed light for improving dry eye disease in rosacea. J Am Acad Dermatol. 2020 ; 83 : e105.
PubMed
54) Waszczykowska A, Zyro D, Jurowski P, et al. Effect of treatment with silver (I) complex of metronidazole on ocular rosacea : design and formulation of new silver drug with potent antimicrobial activity. J Trace Elem Med Biol. 2020 ; 61 : 126531.
 
55) Donmez O, Akova YA. Pediatric ocular acne rosacea : clinical features and long term follow-up of sixteen cases. Ocul Immunol Inflamm. 2021 ; 29 : 57-65.
PubMed
56) Schaller M, Almeida LM, Bewley A, et al. Rosacea treatment update : recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017 ; 176 : 465-71.
PubMed
57) Graves LL, Hoopman J, Finn R. Carbon dioxide laser resurfacing for rhinophyma : a case report and discussion of the literature. J Oral Maxillofac Surg. 2020 ; 78 : 2296 e2291-7.
 
58) Schmitz L, Hessam S, Scholl L, et al. Wound care with a porcine extracellular matrix after surgical treatment of rhinophyma. J Cutan Med Surg. 2020 ; 24 : 253-8.
PubMed
59) Walsh RK, Endicott AA, Shinkai K. Diagnosis and treatment of rosacea fulminans : a comprehensive review. Am J Clin Dermatol. 2018 ; 19 : 79-86.
 
60) Nowak M, Baranska-Rybak W, Mehrholz D, et al. Rosacea fulminans-coincidence of the disease with inflammatory bowel disease. J Eur Acad Dermatol Venereol. 2019 ; 33 : e247-8.
PubMed
61) Garayar Cantero M, Garabito Solovera E, Aguado Garcia A, et al. Use of permethrin in the treatment of rosacea fulminans during pregnancy : one case report. Dermatol Ther. 2020 ; 33 : e13436.
PubMed
62) Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea : Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002 ; 46 : 584-7.
PubMed
63) Merlo G, Cozzani E, Russo R, et al. Dapsone for unresponsive granulomatous rosacea. Am J Ther. 2020 ; 27 : e304-6.
PubMed
64) Liu RC, Makhija M, Wong XL, et al. Treatment of granulomatous rosacea with chromophore gel-assisted phototherapy. Photodermatol Photoimmunol Photomed. 2019 ; 35 : 280-1.
PubMed
65) Ansorge C, Technau-Hafsi K. Granulomatous rosacea in a lung transplant recipient : a possible therapy option in a unique group of patients. Hautarzt. 2020 ; 71 : 134-8.
 
66) Kok WL, Oon HH, Giam YC. A case report of granulomatous rosacea of the face. Singapore Med J. 2018 ; 59 : 228-9.
PubMed
P.30 掲載の参考文献
1) Dirschka T, Szliska C, Jackowski J, et al. Impaired skin barrier and atopic diathesis in perioral dermatitis. J Dtsch Dermatol Ges. 2003 ; 1 : 199-203.
PubMed
2) Searle T, Ali FR, Al-Niaimi F. Perioral dermatitis : diagnosis, proposed etiologies and management. J Cosmet Dermatol. 2021 ; 20 : 3839-48.
PubMed
3) Ehmann L, Reinholz M, Maier T, et al. Efficacy and safety results of a drug-free cosmetic fluid for perioral dermatitis : the Toleriane Fluide Efficacy in Perioral Dermatitis (TOLPOD) Study. Ann Dermatol. 2014 ; 26 : 462-8.
PubMed
4) Schwarz T, Kreiselmaier I, Bieber T, et al. A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. J Am Acad Dermatol. 2008 ; 59 : 34-40.
PubMed
5) Oppel T, Pavicic T, Kamann S, et al. Pimecrolimus cream (1%) efficacy in perioral dermatitis-results of a randomized, double-blind, vehicle-controlled study in 40 patients. J Eur Acad Dermatol Venereol. 2007 ; 21 : 1175-80.
PubMed
6) Ollech A, Yousif R, Kruse L, et al. Topical calcineurin inhibitors for pediatric periorificial dermatitis. J Am Acad Dermatol. 2020 ; 82 : 1409-14.
PubMed
7) Bribeche MR, Fedotov VP, Jillella A, et al. Topical praziquantel as a new treatment for perioral dermatitis : results of a randomized vehicle-controlled pilot study. Clin Exp Dermatol. 2014 ; 39 : 448-53.
PubMed
8) Srour J, Bengel J, Linden T, et al. Efficacy of a skin care cream with TRPV1 inhibitor 4-t-butylcyclohexanol in the topical therapy of perioral dermatitis. J Cosmet Dermatol. 2020 ; 19 : 1409-14.
 
9) Boeck K, Abeck D, Werfel S, et al. Perioral dermatitis in children--clinical presentation, pathogene sis-related factors and response to topical metronidazole. Dermatology. 1997 ; 195 : 235-8.
 
10) Goel NS, Burkhart CN, Morrell DS. Pediatric periorificial dermatitis : clinical course and treatment outcomes in 222 patients. Pediatr Dermatol. 2015 ; 32 : 333-6.
PubMed
11) Jansen T. Azelaic acid as a new treatment for perioral dermatitis : results from an open study. Br J Dermatol. 2004 ; 151 : 933-4.
PubMed
12) Liu ZH, Du XH. Quality of life in patients with facial steroid dermatitis before and after treatment. J Eur Acad Dermatol Venereol. 2008 ; 22 : 663-9.
PubMed
13) Veien NK, Munkvad JM, Nielsen AO, et al. Topical metronidazole in the treatment of perioral dermatitis. J Am Acad Dermatol. 1991 ; 24 : 258-60.
PubMed
14) Milagre ACX, Almeida APM, Rezende HD, et al. Granulomatous perioral dermatitis with extra-facial involvement in childhood : good therapeutic response with oral azithromycin. Rev Paul Pediatr. 2018 ; 36 : 511-4.
PubMed
15) Hatanaka M, Kanekura T. Case of childhood granulomatous periorificial dermatitis. J Dermatol. 2018 ; 45 : e256-7.
PubMed
16) Noguera-Morel L, Gerlero P, Torrelo A, et al. Ivermectin therapy for papulopustular rosacea and periorificial dermatitis in children : a series of 15 cases. J Am Acad Dermatol. 2017 ; 76 : 567-70.
 
17) Richey DF, Hopson B. Photodynamic therapy for perioral dermatitis. J Drugs Dermatol. 2006 ; 5 : 12-6.
PubMed
18) von Csiky-Sessoms S. Intralesional steroids for the management of periorificial granulomatous dermatitis. J Drugs Dermatol. 2019 ; 18 : 955.
 
P.32 掲載の参考文献
1) Chovatiya RJ, Colegio OR. Demodicosis in renal transplant recipients. Am J Transplant. 2016 ; 16 : 712-6.
PubMed
2) Forton F, Seys B, Marchal JL, et al. Demodex folliculorum and topical treatment : acaricidal action evaluated by standardized skin surface biopsy. Br J Dermatol. 1998 ; 138 : 461-6.
PubMed
3) Forton FMN, De Maertelaer V. Treatment of rosacea and demodicosis with benzyl benzoate : effects of different doses on Demodex density and clinical symptoms. J Eur Acad Dermatol Venereol. 2020 ; 34 : 365-9.
PubMed
4) Forstinger C, Kittler H, Binder M. Treatment of rosacea-like demodicidosis with oral ivermectin and topical permethrin cream. J Am Acad Dermatol. 1999 ; 41 : 775-7.
 
5) Clyti E, Nacher M, Sainte-Marie D, et al. Ivermectin treatment of three cases of demodecidosis during human immunodeficiency virus infection. Int J Dermatol. 2006 ; 45 : 1066-8.
PubMed
6) Allen KJ, Davis CL, Billings SD, et al. Recalcitrant papulopustular rosacea in an immunocompetent patient responding to combination therapy with oral ivermectin and topical permethrin. Cutis. 2007 ; 80 : 149-51.
 
7) Mueller RS. Treatment protocols for demodicosis : an evidence-based review. Vet Dermatol. 2004 ; 15 : 75-89.
PubMed
8) Darji K, Burkemper NM. Pityriasis folliculorum : response to topical ivermectin. J Drugs Dermatol. 2017 ; 16 : 1290-2.
PubMed
9) Mueller RS, Bensignor E, Ferrer L, et al. Treatment of demodicosis in dogs : 2011 clinical practice guidelines. Vet Dermatol. 2012 ; 23 : 86-96, e20-81.
 

書評

最近チェックした商品履歴

Loading...